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Background: Concomitant platinum-based chemotherapy and radiotherapy (CT-RT) is the recommended treatment
for unresectable locally advanced stage III non-small cell lung cancer (NSCLC). We conducted a phase II study to
evaluate the efficacy and safety of fractionated oral vinorelbine with cisplatin as induction CT followed by CT-RT.
Methods: Patients with stage III NSCLC received 2 induction cycles of intravenous vinorelbine 25 mg/m2 and
cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8. Responding patients received 2 more cycles
of cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 concomitantly with radiotherapy
2 Gy daily, 5 days/week for a total of 66 Gy.
Results: Seventy patients, median age 61 years, were enrolled. Overall response rate (ORR) was 50.0%; Disease
Control Rate was 81.42%. Median PFS was 14.58 months [95% CI, 10.97-18.75]. Median OS was 17.08 months
[95% CI, 13.57-29.57]. One-year and 2-year survival rates were 68.6% [95% CI, 57.7-79.4] and 37%. One patient
had a grade 3 pulmonary radiation injury and 26.5% had graded 1/2 esophagitis.
Conclusion: In non-operable IIIA-IIIB NSCLC, the combination oral vinorelbine (fractionated fixed dose) plus
cisplatin, during concomitant CT-RT, could offer a well-tolerated option, with comparable activity to I.V.
vinorelbine-based chemoradiotherapy regimens.
Trial registration: ClinicalTrials.gov, NCT01839032
Keywords: Locally advanced non-small cell lung cancer, Oral vinorelbine, ChemoradiotherapyBackground
Lung cancer is a global public health issue worldwide,
with 1.38 million of deaths in 2008 [1]. Non-small cell
lung cancer (NSCLC) is the predominant histological
type accounting for nearly 85% of all lung cancers [2].
At diagnosis, at least, one third of patients have a locally
advanced (stage III) disease [3].* Correspondence: zalcman-g@chu-caen.fr
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reproduction in any medium, provided the orMost patients with stage IIIA (N2) and IIIB NSCLC
cannot undergo complete surgical resection. Up-front
concomitant platinum based chemotherapy and radio-
therapy are currently recommended [4,5]. Cisplatin-
based chemotherapy increases radiotherapy-induced cell
lethal DNA lesions, along with eradication of distant
micrometastases and some other cytotoxic e.g. vinorel-
bine have a supra-additive effect by inducing cell cycle
synchronization into the radiosensitive G2M phase.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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for the treatment of NSCLC and breast cancer [6] avail-
able in intravenous and oral formulations, oral vinorelbine
provides similar efficacy to intravenous vinorelbine, while
offering benefits in terms of convenience, ease of adminis-
tration, as well as satisfying patient preference [7,8].
The combination vinorelbine/cisplatin is considered as
one of the standard regimens for concomitant CT-RT in
unresectable locally advanced stage III NSCLC [4]. An
optimal efficacy/tolerance ratio was achieved with vinorel-
bine/cisplatin when compared with gemcitabine/cisplatin
or paclitaxel/cisplatin [9]. We aimed to evaluate, the
tolerance and efficacy, a new schedule of oral frac-
tionated vinorelbine formulation, at fixed dosing with
cisplatin, concomitantly with radiotherapy, following
induction chemotherapy with vinorelbine/cisplatin in
unresectable stage III NSCLC.
Methods
This phase II, multicenter, single-arm open-label study
was conducted in France. Patients with histologically or
cytologically confirmed stage IIIA (only N2), and dry
IIIB previously untreated inoperable NSCLC, 18 to
75 years old, Karnofsky Performance Status (KPS) ≥ 80%,
weight loss ≤ 10% within the previous 3 months, and
normal organ functions were eligible. They had at least
one measurable lesion according to Response Evaluation
Criteria in Solid Tumors (RECIST version 1.0) [10].
The study was approved by the ethics committee (CPP
Nord-Ouest IV) and was registered in clinicaltrials.gov
(NCT00295672). It was conducted in accordance with
the declaration of Helsinki and in compliance with Good
Clinical Practice guidelines. All patients provided infor-
med consent prior to any study procedure.
Treatment plan
Chemotherapy
During the induction period (IP), patients received
chemotherapy for two 3-week cycles. Bolus intravenous
vinorelbine 25 mg/m2, was administered on day 1, then
cisplatin 80 mg/m2 was administered over 1-hour infu-
sion. Oral Vinorelbine 60 mg/m2 was also administered
on day 8.
Patients with progressive disease (PD) at the end of
the IP were withdrawn from the study, but followed for
survival assessment. Patients with objective response (OR)
or no change (NC) continued the concomitant period
(CP) including two additional 3-week cycles of chemo-
therapy with concomitant radiotherapy (Figure 1). During
CP, vinorelbine was administered at the fractionated oral
dose of 20 mg on days 1, 3, and 5. Cisplatin 80 mg/m2 was
administered on day 1 (Figure 2).
The administration of vinorelbine was delayed by one
week for an absolute neutrophil count (ANC) <1.5 × 109/Land/or platelet count <75 × 109/L. Treatment with
growth factors was allowed for febrile neutropenia or
neutropenic infection. Vinorelbine was postponed or
stopped for neurological toxicity graded ≥ 2 or liver tox-
icity. The cisplatin dose was reduced by 50%, postponed
or stopped based on creatinine clearance. Symptomatic
ototoxicity led to 50% reduction of cisplatin dose.
Radiotherapy
Radiotherapy, 2 Gy fractions daily, 5 days a week for a total
dose of 66 Gy started on day 1 of the CP. 3D-RT was deliv-
ered with a curative intent with a 3D conformal field. Tar-
get volumes were delineated according to the International
Commission on Radiation Units and Measurements-62
(ICRU 62): Gross Tumor Volume (GTV) included the
tumor (GTV t) and involved nodes (GTV n). The Clinical
Target tumor Volume (CTV t), was automatically gener-
ated by adding a 5 to 8 mm 3D expansion to the GTV.
The Clinical Target tumor and node Volume (CTV t + n)
was the addition of CTV t, ipsilateral hilum and ipsilateral
mediastinum. The ipsilateral supra clavicular fossa was
included only if the tumor was located in the upper lobe.
The Planning Target Volume (PTV) was obtained by add-
ing a minimum of 10 mm 3D expansion to CTV. The
structures of interest were delineated on dosimetric CT
scans. The target goal for the PTV t + n was that ≥95% of
PTV t + n receives 100% of the prescribed dose, but no
more than 107%.
Radiotherapy was discontinued in case of patient’s
decision, progression, side effects or comorbidities non-
compatible with radiation, ANC <500/mm3 and/or febrile
neutropenia and/or platelets <50,000 mm3.
Study assessments
Tumor assessments were performed at the end of the IP
and at the end of the CP. Patients were followed for
safety during the treatment and 30 days after the last
treatment administration: Laboratory tests were perfor-
med before each cycle. Toxicity was graded according to
the National Cancer Institute Common Toxicity Criteria
(NCI CTC) version 2.0. A complete clinical examination
was performed at the end of each cycle. Tumor response
was assessed according to RECIST criteria version 1.0,
every 3 months for 2 years and then every 6 months until
death. Unconfirmed responses were considered as NC.
CT-scans of responders and borderline patients were
reviewed by an expert thoracic radiologist.
Endpoints and statistical analysis
Fleming one-sample multiple-testing procedure for phase
II clinical trials was used [11]. A total of 65 patients were
enrolled to obtain 60 evaluable patients allowing for a type
I error of less than 5% and type II error of less than 10%
Registered / treated patients
(n=70)





No histologically or cytologically confirmed 
diagnosis of NSCLC cancer stage IIIA-IIIB (n=2)
Stade VI confirmed after inclusion (n=2)
Completed induction CT
(n=69)
Reason for treatment discontinuation
Adverse event (Grade 3 fatigue) (n=1)
Entered CT-RT
(n=49)
Reason for treatment discontinuation (n=20)
Progressive Disease (n= 5)
Adverse event/excessive toxicity (n=5)
Metastases at study entry, patient withdrawn from the study (n=2)
Death for progression (n=1)
Death for neither progression nor toxicity (n=1)
Protocol violation leading to withdrawal from the study (n=2)
Surgery at the end of induction (n=4)
Completed CT-RT
(n=47)
Reason for treatment discontinuation (n=2)
Protocol violation (RT stopped at 50, 4 Gy) (n=1)
Disease progression (n=1) 
Figure 1 Patients disposition.
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hypothesis (H1) of 70%.
The primary endpoint was best OR according to
RECIST criteria in evaluable patients. The OR rate (ORR)
was expressed as the sum of the percentage of complete
response (CR) and partial response (PR). The Disease
Control Rate (DCR) was defined as the sum of the OR
and the NC rates.
Secondary endpoints were progression-free survival
(PFS), and overall survival (OS), calculated by the Kaplan-
Meier method in the Intent to Treat Population (ITT), and
duration of response (DR). The safety analysis reported the




A total of 70 patients were enrolled between October
2005 and May 2008 and 69 completed induction therapy.Among the 49 patients who started consolidation treat-
ment, 47 patients completed concomitant CT-RT. The
reasons for treatment interruption were protocol deviation
(n = 1) and tumor progression (n = 1) (Figure 1).
All included patients were evaluable for safety and 64
for best tumor response.
Overall, 84.3% were men, median age was 61 years
[39.5-73.8] and median KPS was 90% [80-100%]. Approxi-
mately, 2/3 of patients had stage IIIB disease (Table 1).
Drug exposure
A total of 237 cycles were administered during a median
duration of treatment of 12.4 [3-15] weeks. Forty nine
patients (70%) received the planned 4 cycles (see Table,
Additional file 1, which details drug exposure).
During the IP, the median dose intensity (DI) and
median relative DI were 18.2 mg/m2/week and 90.8% for
oral vinorelbine respectively and 7.8 mg/m2/week and
94.2% for intravenous vinorelbine. During the CP, they
Figure 2 Treatment schedule.
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five patients (50.7%) had at least one cycle delayed by ≥4
days. Such delays were recorded for 43 (25.7%) cycles;
only 13 were due to drug related toxicities (n = 12).
The median dose of radiotherapy was 66 Gy [50–67].
Efficacy
The Best Overall Response was assessed by an independ-
ent thoracic radiologist: 5 patients achieved a CR
(7.14%), 27 patients were in PR (38.57%) and 25 had NC
(35.5%), leading to an ORR of 50.0% [95% CI, 37.2-58.1],
leading to reject the H0 null hypothesis of inefficacy, ac-
cording to the statistical design. Disease Control Rate
(DCR) was 81.43% [95% CI, 70.34-89.72] (Table 2). Four
patients became operable at the end of the IP. Two pa-
tients died at 7 months and 16 months after surgery, 2
patients were still alive (16 and 33 months after surgery)
at the time of the cut-off.
At the analysis performed on September 29th, 2009,
the median DR was not reached meaning that more than
50% of patients were still controlled at a median follow-
up of 19.08 months [95% CI, 16.00-24.11].
Disease progression was reported for 51 patients. Re-
lapses were loco-regional for 16 patients (22.9%), distantfor 21 (30%) and, mixed for 5 (7.1%). The most frequent
sites of disease progression were brain (17.1%), liver (8.6%)
and bone (8.6%) (see Table, Additional file 2, which de-
tailed sites of disease progression). Nine patients (12.9%)
had a clinical progression, including general health deteri-
oration (n = 2), respiratory insufficiency (n = 2), cataclys-
mic hemoptysis (n = 1), cataclysmic hemorrhage (n = 1),
general fatigue (n = 1). No more details were reported for
2 patients.
Median PFS was 14.58 months [95% CI, 10.97-18.75]
(Figure 3) and PFS rate at 12 months was 58.6% [95%
CI, 47–70.1] (Table 3).
At a median follow-up of 37 months, median OS was
17.08 months [95% CI, 13.57-29.57] with 1-year survival
rate of 68.6% [95% CI, 57.7-79.4] (Figure 4). The 2-year
survival rate was 37% (Table 3). Survival rates were higher
in squamous (vs. non-squamous cell cancer patients) and
stage IIIA patients (vs. IIIB patients) (see Table, Additional
file 3, Overall survival rates according to histological type
and disease stage).
Safety
During the IP, Grade 3–4 leucopenia and neutropenia
were reported for 8.6% and 24.3% of patients respectively.
Table 1 Patient characteristics at baseline (ITT population,
n = 70)
n (%)
Median age, years (range) 61 (39.5-73.8)
35–49 years 10 (14.3%)
50–64 years 36 (51.4%)









Squamous cell 31 (44.3%)
Adenocarcinoma 23 (32.9%)
Large cell Carcinoma 13 (18.6%)





Median delay between diagnosis
and study entry, months (range)
1 (0.2-6.4)
*Stage IV: Dubious at inclusion, was confirmed at following evaluations.
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Esophagitis was reported in 13 patients (26.5%), all grade
1–2. One patient had a grade 3 pulmonary radiation in-
jury, he died 4 months after the start of the event and one
patient had a grade 1 radiation pneumonitis. Safety results
are detailed in Table 4.Table 2 Best Overall Response (Evaluable population,
n = 64)
Evaluable population n = 64
Complete response 5 (7.81%)
Partial response 27 (42.18%)
No change 25 (39.06%)
Progression disease 8 (12.5%)
Non evaluable* 6 (9.37%)
Objective response rate 32 (50.0%)
Disease control rate 57 (89.06%)
Median duration of the response** Not reached
All scans of responding and/or border line stable patients were reviewed by
an independent panel review.
*5 NE: (2 patients were not eligible, 3 patients had adverse events avoiding
evaluation, for 1 patient, RECIST measurements were never obtained since initial
CT-scan was lost).
**Median Duration of the response was not reached at the cut-off date (29/12/2009).Discussion
Over the last decades, the standard treatment for unresect-
able locally advanced NSCLC has evolved, from radiother-
apy alone [12], to full dose up-front concomitant CT-RT.
Two meta-analyses reported that both sequential CT-RT
and concomitant CT-RT provide a benefit over radio-
therapy alone [13,14]. However, the prognosis for stage III
NSCLC remains poor with a 5-year survival rate of less
than 20% with CT-RT. The study by Furuse was the first
phase III showing a significantly higher median survival in
the concomitant arm compared to the sequential arm
(16.5 months vs. 13.3 months; p = 0.04) and 2-year survival
rates of respectively 34.6% and 27.4%, confirmed by a
significantly better 5-year survival (15.8% vs. 8.9%). In this
trial using the MVP (mitomycin/vindesine/cisplatin) triplet,
myelosuppression was significantly more frequent in the
concomitant arm (p < .0001), with surprisingly identical
esophageal toxicity [15]. A meta-analysis on 1,205 patients
with unresectable locally advanced NSCLC confirmed that,
compared to sequential CT-RT, concomitant CT-RT im-
proves 5-year survival from 10.6% to 15.1% (HR = 0.84,
[95% CI, 0.74-0.95], p = 0.004). Two-year survival was
30.3% and 35.6% respectively [16]. The question on the
potential benefit of induction chemotherapy preceding a
concomitant CT-RT remains unanswered.
Subsequent trials mainly used cisplatin plus etoposide
with concomitant radiotherapy. However, this doublet was
replaced in stage IV patients by more efficient new-
generation cisplatin-based doublets (including vinorelbine,
taxanes, gemcitabine and more recently pemetrexed).
The phase II CALGB 9431 study first investigated
cisplatin/gemcitabine or cisplatin/paclitaxel or cisplatin/
intravenous vinorelbine as induction chemotherapy
followed by concomitant CT-RT for stage IIIB NSCLC.
Median overall survival was 17.7 months for the vinorel-
bine arm, with 1-year and 2-year survival of 65% and 40%
respectively. Grade 3–4 Esophagitis was more frequent
with gemcitabine than with vinorelbine [9].
In the NPC 95–01 trial, 3 cycles of cisplatin (120 mg/m2
on day 1) plus weekly I.V. 30 mg/m2 vinorelbine in the
sequential arm, were compared with 2 cycles of cisplatin/
etoposide with concomitant radiotherapy, followed by
2 cycles of cisplatin (80 mg/m2) plus weekly vinorelbine.
Although the difference was not statistically significant
due to a lack of power, the median survival of 16.3 months
(95% CI, 5.8-34.8) in the concomitant arm was numeric-
ally higher than the 14.5 months (95% CI, 8.3-27.4) in the
sequential arm (p = 0.24). The 2-year survival rates were
39.3% (95% CI, 29.7-48.9) and 26.5% (95% CI, 17.9-35)
respectively. Grade 4 neutropenia was higher in the se-
quential arm (72% vs. 48%, p = 0.008) as was grade 3–4
esophageal toxicity in the concomitant arm (32% vs. 3%,
p < 0.001). Grade 3–4 radiation pneumonitis (11% vs. 5%)
was numerically higher in the sequential arm. Toxic
Median PFS (months)

















Figure 3 Progression free survival (ITT).
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and 9.6% respectively [17].
Induction chemotherapy with cisplatin and I.V. vinorel-
bine followed by concomitant docetaxel and radiotherapy
in responding patients had been also assessed in a French
phase II trial, the median survival was 13 months
[0.3-44.9] [18].
More recently, Horinouchi et al. reported the pool
long term results of two consecutive Japanese phase I
and II trials, using up-front concomitant chemoradio-
therapy with 4 or 3 cycles of I.V. vinorelbine (Day 1 and 8)
plus cisplatin. In addition, the second trial also included
three cycles of docetaxel consolidation monotherapy. A
very high 82.0% objective response rate was reported,
whereas the 21.0% 3-year progression-free rate, as the me-
dian PFS (13.4 months) were more classical. The pool me-
dian overall survival was surprisingly long (30.0 months),
but could be explained by inclusion of a large majority of
adenocarcinoma patients (64%), as usual in Asian trials,
contrasting with the recruitment of our current trial,
which included only 35% of adenocarcinoma [19].
In our trial, we chose vinorelbine for its availability in an
oral formulation, thus allowing fractionated use withoutTable 3 PFS and survival results (ITT population)
ITT population n = 70
Median progression free survival, months 14.58 [95% CI; 10.97-18.75]
Progression free survival rate at
12 months, %
58.6 [95% CI; 47.0-70.1]
Median overall survival, months 17.08 [95% CI; 13.56-29.57]
Survival rate at 6 months, % 88.6 [95% CI; 81.1-96.0]
Survival rate at 12 months, % 68.6 [95% CI; 57.7-79.4]
Survival rate at 18 months, % 43.4 [95% CI; 31.3-55.6]
Survival rate at 24 months, % >37*
*95% CI was not estimated (data were not mature).increasing hospital visits, with, as a consequence, a cost-
effective impact.
An international phase II trial used induction che-
motherapy with oral vinorelbine/cisplatin followed by
concomitant CT-RT and oral vinorelbine/cisplatin, with
a different schedule, and led to a median survival of
23.4 months (95% CI, 17.6-29.8) and a promising 2-year
survival of 48.1%. The toxicity profile showed 27.8% of
grade 3–4 neutropenia, 9.3% of grade 3–4 vomiting dur-
ing the induction chemotherapy, and only 4.3% of grade
3 esophageal toxicity. Two deaths occurred after 2 cycles
(massive hemoptysis, cardiac failure) [20].
More recently, the French GFPC 05–03 phase II study
assessed induction chemotherapy but with docetaxel/cis-
platin, followed by concomitant oral vinorelbine/cisplatin
and radiotherapy. Median survival was 20.8 months (95%
CI, 13.7-24.1) while 1-year and 2-year survivals were
66.1% (95% CI, 52.1-76.8) and 37.1% (95% CI, 23.3-50.9)
respectively. During the induction chemotherapy, grade
3–4 neutropenia was 28.6%, 6 patients stopped treatment
for toxicity and 1 patient died. During the CT-RT, 3 pa-
tients had grade 3 esophagitis and only one patient had
graded 2 radiation pneumonitis (2.6%) [21].
Conversely, we chose to avoid strategies based on add-
ing a consolidation or a maintenance therapy since two
phase III trials had been terminated early on the evidence
of futility of treatments and an increase of toxicities. One
trial evaluated consolidation docetaxel after concomitant
CT-RT and the other evaluated maintenance therapy by
gefitinib after consolidation docetaxel following concomi-
tant CT-RT [22,23].
In our study, we evaluated induction chemotherapy with
vinorelbine/cisplatin followed by concomitant CT-RT in
unresectable stage III NSCLC with the same regimen. We
used intravenous and oral vinorelbine during the IP and
only oral vinorelbine for the CT-RT. The objective ORR
Median OS (months)
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Figure 4 Overall survival (ITT).
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was comparable to the ORR of 41.1% in Descourt et al.
trial and 53.7% [95% CI, 39.6-67.4] in Krzakowski et al.
study [19,20]. Also, the DCR of 81.4% was high. The ORR
was consistent with the median survival of 17.08 months,Table 4 Hematological, clinical and radiation toxicities per pa
Induction therapy (n =
All grades



















Pulmonary radiation injury -
Radiation mucositis -
Pneumonitis -
Acute renal failure observed in 1 patient (G3 at induction).
Acute radiation pneumonitis at 30 days post-completion observed for 1 patient.and the 1-year and 2-year survivals of 68.6% and 37%
respectively. These efficacy results are similar to those
reported in recent trials and also in other studies which
evaluated vinorelbine/cisplatin using the same therapeutic
strategy.tient (NCI/CTC) (ITT population, n = 70)
70), n (%) Consolidation therapy (n = 49), n (%)
Grade 3-4 All grades Grade 3-4
- 39 (79.6) 2 (4.1)
17 (24.3) 20 (40.8) 1 (2)
6 (8.6) 30 (61.2) 1 (2)
- 11 (22.4) -
-
2 (2.9) 23 (46.9) -
1 (1.4) 15 (30.6) 1 (2)
2 (2.9) 10 (20.4) 1 (2)
- 5 (10.2) -
- 2 (4.1) -
- 3 (6.1) 1 (2)
- - -
- 13 (26.5) -
- 12 (24.5) -
- 6 (12.2) -
- 3 (6.1)
- 1 (2) 1 (2)
- 1 (2) -
- 1 (2) -
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applied as the proportion of patients regarding tumor
histology differed in the various published trials and this
may have confounded the comparison.
Whereas concomitant CT-RT is known to increase
radiation toxicities, in our trial the treatment was well
tolerated and no grade 3 or 4 esophagitis was re-
ported, suggesting a better esophageal toxicity profile
for vinorelbine, as previously reported for vindesine
in MVP regimen. We only observed 8.6% grade 3–4
leukopenia, 24.3% grade 3–4 neutropenia, and 2.85%
grade 4 febrile neutropenia. Treatment discontinu-
ation due to toxicity was reported in 5 patients, at
the end of the IP, but none during the CP. Only one
patient had a grade 3 radiation pneumonitis. This fa-
vorable toxicity profile is important for quality of life
and is not associated with a lower efficacy as may
have been feared.
Therefore, this regimen including oral vinorelbine
seems to offer a favorable safety profile coupled with
similar efficacy when used concomitantly with RT.Conclusion
In conclusion, this new fractionated fixed dose ad-
ministration of oral vinorelbine concomitantly with
cisplatin and radiotherapy, following induction vino-
relbine/cisplatin is feasible, and offers a well-tolerated
(in terms of esophageal and hematological toxicities)
therapeutic option, in non-operable IIIA-IIIB NSCLC.
The activity of this oral regimen seems comparable to
most data previously published with I.V. vinorelbine
regimens. However, a trial comparing concomitant oral
vinorelbine/cisplatin and radiotherapy, preceded or
not by induction vinorelbine/cisplatin, with concur-
rent I.V. vinorelbine/cisplatin and radiotherapy would
be now needed, to confirm these encouraging results
and to assess cost-effectiveness of such an out-patient
regimen.Additional files
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